Holen Sie sich die Stockscreener-App
12.92
2.78%
0.35
Schlusskurs vom Vortag:
$12.57
Offen:
$12.57
24-Stunden-Volumen:
8.59M
Relative Volume:
1.47
Marktkapitalisierung:
$8.82B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
2.2867
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
+8.30%
1M Leistung:
+11.09%
6M Leistung:
+20.75%
1J Leistung:
+5.99%
1-Tages-Spanne:
$12.54
$13.04
1-Wochen-Bereich:
$11.94
$13.08
52-Wochen-Spanne:
$8.73
$13.08
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Vergleichen Sie ROIV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
12.92 | 8.58B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-02 | Eingeleitet | Citigroup | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Should I hold or sell Roivant Sciences Ltd. nowProfit Target & Capital Protection Trading Alerts - خودرو بانک
What is the cash position of Roivant Sciences Ltd.Market Sentiment Report & Real-Time Stock Price Movement Reports - خودرو بانک
Real time pattern detection on Roivant Sciences Ltd. stockJuly 2025 Opening Moves & Detailed Earnings Play Strategies - Newser
Is Roivant Sciences Ltd. stock undervalued right nowTrade Performance Summary & Growth Focused Entry Reports - خودرو بانک
Roivant Sciences Ltd. stock trend outlook and recovery pathWeekly Profit Recap & Stepwise Trade Signal Guides - Newser
Candlestick signals on Roivant Sciences Ltd. stock todayQuarterly Earnings Report & Safe Entry Point Alerts - Newser
Order flow analysis tools used on Roivant Sciences Ltd.July 2025 Macro Moves & Free Technical Pattern Based Buy Signals - Newser
Can Roivant Sciences Ltd. outperform in the next rallyJuly 2025 Weekly Recap & Weekly High Momentum Picks - خودرو بانک
What machine learning models say about Roivant Sciences Ltd.Portfolio Return Report & Long-Term Growth Plans - Newser
Tools to monitor Roivant Sciences Ltd. recovery probabilityWeekly Trend Report & Entry and Exit Point Strategies - Newser
Is Roivant Sciences Ltd. stock a good hedge against inflationJuly 2025 Retail & Risk Adjusted Buy/Sell Alerts - Newser
Is Roivant Sciences Ltd. stock bottoming outEarnings Recap Report & Weekly High Conviction Ideas - Newser
Combining price and volume data for Roivant Sciences Ltd.2025 Key Highlights & Consistent Return Investment Signals - Newser
Will Roivant Sciences Ltd. outperform the marketMarket Weekly Review & Safe Capital Growth Trade Ideas - Newser
Roivant Sciences stock hits 52-week high at 13.06 USD - Investing.com
How institutional ownership impacts Roivant Sciences Ltd. stockWeekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Can swing trading help recover from Roivant Sciences Ltd. lossesIndex Update & Risk Controlled Swing Trade Alerts - Newser
Roivant Sciences' Mosliciguat Granted Orphan Drug Designation in Japan - MarketScreener
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewswire Inc.
Signal Recap: How volatile is Roivant Sciences Ltd. stockJuly 2025 Pullbacks & Low Risk Investment Opportunities - خودرو بانک
Automated trading signals detected on Roivant Sciences Ltd.Quarterly Profit Report & Daily Entry Point Trade Alerts - Newser
How to build a custom watchlist for Roivant Sciences Ltd.Portfolio Performance Report & Long-Term Capital Growth Strategies - Newser
Should you hold or exit Roivant Sciences Ltd. nowIPO Watch & Long-Term Capital Growth Strategies - Newser
What candlestick patterns are forming on Roivant Sciences Ltd.July 2025 Fed Impact & Smart Investment Allocation Tips - Newser
Is Roivant Sciences Ltd. backed by strong institutional buying2025 Short Interest & Daily Entry Point Alerts - خودرو بانک
Transcript : Roivant Sciences Ltd.Special Call - MarketScreener
Forecasting Roivant Sciences Ltd. price range with options data2025 Breakouts & Breakdowns & Free Expert Verified Stock Movement Alerts - Newser
Will Roivant Sciences Ltd. see short term momentumMarket Sentiment Report & Real-Time Buy Signal Notifications - Newser
Using RSI to spot recovery in Roivant Sciences Ltd.July 2025 Pullbacks & Free Growth Oriented Trading Recommendations - Newser
Short interest data insights for Roivant Sciences Ltd.July 2025 Gainers & Free Real-Time Volume Trigger Notifications - Newser
Can Roivant Sciences Ltd. ride the EV waveQuarterly Trade Review & Weekly Stock Performance Updates - خودرو بانک
Technical analysis overview for Roivant Sciences Ltd. stock2025 Bull vs Bear & Growth Focused Entry Point Reports - Newser
Is Roivant Sciences Ltd. forming a reversal patternEarnings Summary Report & AI Driven Stock Movement Reports - Newser
Will a bounce in Roivant Sciences Ltd. offer an exitJuly 2025 PreEarnings & Weekly High Momentum Picks - Newser
Roivant Sciences Ltd. stock daily chart insightsJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - Newser
Citi Initiates Roivant Sciences(ROIV.US) With Buy Rating, Announces Target Price $16 - 富途牛牛
Roivant Sciences stock rating reiterated by TD Cowen ahead of trial data - Investing.com UK
Citigroup initiates coverage on Roivant Sciences with Buy rating and $16 price target. - AInvest
How to monitor Roivant Sciences Ltd. with trend dashboardsWeekly Market Report & Capital Efficiency Focused Ideas - Newser
Will Roivant Sciences Ltd. bounce back from current supportEarnings Recap Summary & Daily Entry Point Alerts - Newser
Trading Bots Trigger Alerts on Roivant Sciences Ltd. Activity getLinesFromResByArray error: size == 0 - thegnnews.com
How to use Fibonacci retracement on Roivant Sciences Ltd.Portfolio Return Report & Safe Entry Zone Identification - Newser
Analyzing Roivant Sciences Ltd. with risk reward ratio chartsJuly 2025 Price Swings & Expert Curated Trade Setup Alerts - Newser
Chart overlay techniques for tracking Roivant Sciences Ltd.Stop Loss & Verified Stock Trade Ideas - Newser
Building trade automation scripts for Roivant Sciences Ltd.Global Markets & Proven Capital Preservation Tips - Newser
Identifying reversal signals in Roivant Sciences Ltd.July 2025 Fed Impact & AI Driven Price Forecasts - Newser
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ramaswamy Vivek | 10% Owner |
Sep 05 '25 |
Sale |
12.96 |
385,816 |
5,000,175 |
35,508,359 |
| Ramaswamy Vivek | 10% Owner |
Sep 04 '25 |
Sale |
12.92 |
194,933 |
2,518,534 |
35,894,175 |
| Venker Eric | President & Immunovant CEO |
Aug 20 '25 |
Option Exercise |
3.85 |
100,000 |
385,000 |
1,753,585 |
| Venker Eric | President & Immunovant CEO |
Aug 20 '25 |
Sale |
11.72 |
100,000 |
1,172,000 |
1,653,585 |
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):